Background: CLL is a common lymphoid malignancy. Several new chemotherapy protocols have been introduced for treatment of CLL recently, includlllg FC protocol. Purpose: To assess the effectiveness of the FC protocol for treatment of CLL patients. Patients and methods:. Study was carried out on 42 CLL patients treated in NIHBT from 12/2009 to 11/2012. Results: (1) Complete response rate was 47.6 percent
overall response rate (complete and partial response) was 83.3 percent
(2) Clinical condition was improved: percentage of patients with anemia, splenomegaly and Iymphodenopathy before and after treatment were 85.7 percent and 11.9 percent
71.4 percent and 9.5 percent
92.8 percent and 4.8 percent, respectively
(3) Peripheral blood lymphocyte count was decreased gradually and normalized after treatment
(4) Hematological adverse effects: Neutropenia and thrombocytopenia grades 1-2 have been observed in 42.8 percent. Few patients have severe neutropenia (grade 3 - 4.7 percent) and thrombocytopenia (grades 3-4 - 7.1 percent and 4.7 percent, respectively). Conclusion: FC is an effective chemotherapy protocol for treatment of CLL patients.